Former Speaker of the House Newt Gingrich Joins Pathway Genomics’ Advisory Board

Posted on 02/26/2015 in News, Press Releases

Gingrich
SAN DIEGO, CAFebruary 26, 2015Pathway Genomics Corporation, a CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that former Speaker of the U.S. House of Representatives Newt Gingrich has joined its strategic advisory board. A former candidate for president of the United States in 2012, Gingrich has spent more than four decades as a leader in American public life. During his time in Congress, he helped save Medicare from bankruptcy, shepherded FDA reform to help the seriously ill and initiated a new focus on scientific research, prevention and wellness.  

Pathway Genomics Appoints Anja Kammesheidt as Vice President of Research and Development

Posted on 02/19/2015 in News, Press Releases

Anja
SAN DIEGO, CAFebruary 19, 2015 – Pathway Genomics Corporation, a CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced it has named Anja Kammesheidt, Ph.D., as its vice president of research and development. Based at Pathway Genomics’ San Diego headquarters, Dr. Kammesheidt brings more than 15 years of experience to the role. “We are honored to have Dr. Kammesheidt join our organization where she will oversee all assay development activities,” said Jim Plante, Pathway Genomics’ founder and CEO. “We know that her wealth of knowledge will be a major asset to the company and a vital component of reaching our commercial objectives as we move forward.”  

Renowned Genetic Counselors Join Pathway Genomics’ Advisory Board

Posted on 02/10/2015 in News, Press Releases

SAN DIEGO, CAFebruary 10, 2015Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that Jacquelyn Powers, M.S., LCGC, of the Hospital of the University of Pennsylvania, and Ofri Leitner, M.S., CGC, of the University of North Carolina at Chapel Hill, have joined Pathway Genomics’ strategic advisory board. Powers and Leitner are well-respected clinical genetic counselors that are intimately involved in the hereditary cancer programs at their respective institutions.  

Genomics and President Obama’s Precision Medicine Initiative

Posted on 02/06/2015 in Blog Post, Editorial, News

By Corine K. Lau, Ph.D., and Jane Z. Kuo, M.D., Ph.D.

President Obama announced the launch of a new Precision Medicine Initiative during his State of the Union address on January 20, 2015.

What does this mean for you and me?

 

Pathway Genomics Adds Dr. Julie Neidich as New Laboratory Medical Director

Posted on 02/03/2015 in News, Press Releases

SAN DIEGO, CAFebruary 3, 2015Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced today that Julie Neidich, M.D., FACMG, FAAP, has joined our team as the laboratory medical director. Dr. Neidich comes to Pathway Genomics from GeneDx where she was the clinical director of the Whole Exome Sequencing Program. “Dr. Neidich has many years of experience in all aspects of genetic medicine and diagnostics, and she is a tremendous addition to our medical and science team,” said Jim Plante, Pathway Genomics’ founder and CEO.  

Myriad and Pathway Genomics Agree to Settle BRCA Patent Infringement Case

Posted on 01/23/2015 in Blog Post, News, Press Releases

SAN DIEGO, Calif., Jan. 23, 2015 – Pathway Genomics Corporation (“Pathway”) today announced a settlement agreement that ends the BRCA patent litigation against Pathway that began on June 13, 2014. Under the agreement, Myriad Genetics, Inc., the University of Utah Research Foundation, HSC Research and Development Limited Partnership, Endorecherche, Inc., and the Trustees of the University of Pennsylvania (the “Patent Owners”) and Pathway dismiss their respective claims and counterclaims against one another in the BRCA patent litigation. Additionally, the Patent Owners granted a covenant to not sue Pathway under the patents asserted in the litigation proceedings.  

Pathway Genomics Adds The Honorable Dan Glickman, Former US Cabinet Member and Member of Congress, to Strategic Advisory Board

Posted on 12/11/2014 in News, Press Releases

SAN DIEGO, CADecember 11, 2014Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that former U.S. Representative and Secretary of Agriculture Dan Glickman joined its strategic advisory board. “We’re honored to have Secretary Glickman as part of our advisory board,” said Jim Plante, Pathway Genomics’ founder and CEO. “In his 25 years in public service in Congress and as an advisor to the President as Cabinet Member, Dan Glickman distinguished himself as a solutions-oriented leader with impeccable integrity. His many accomplishments over that time speak for themselves, and we are extremely fortunate to now benefit from his vast experience.” Prior to his appointment as Secretary of Agriculture from 1995 until 2001, Glickman served for 18 years in the U.S. House of Representatives representing the 4th Congressional District of Kansas. During his tenure in the House, Glickman emphasized the roles of diet and nutrition in preventing diseases and promoting public health. In 2012 and 2013, Glickman chaired an Institute of Medicine Panel on “Accelerating Progress in Obesity Prevention.” “From a national perspective, I’ve been an advocate for increased prevention as it is clear by all measures that an ounce of prevention is worth a pound of cure,” said Glickman. “Genetics is the new frontier on prevention and Pathway is at the forefront of bringing this new information to physicians so that they can identify the best prevention program for a patient based on their overall risk factors.” Glickman served as Chairman of the Motion Picture Association of America, Inc. (MPAA) from 2004 until 2010, and is the Executive Director of the Aspen Institute Congressional Program, a nongovernmental, nonpartisan educational program for members of the United States Congress.

Pathway Genomics Adds Former US Congressman and Ambassador Tim Roemer to Strategic Advisory Board

Posted on 12/04/2014 in News, Press Releases

SAN DIEGO, CADecember 4, 2014Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced that U.S. Congressman and Ambassador Tim Roemer has joined its strategic advisory board. A former U.S. ambassador to the Republic of India, Congressman Roemer holds a bachelor’s degree from the University of California San Diego, and masters and doctorate degrees in American government from the University of Notre Dame. “During his years of distinguished public service as a Member of Congress and as United States Ambassador to India, Tim Roemer worked tirelessly to improve the lives of people around the world. His success aligns perfectly with our mission at Pathway Genomics. Ambassador Roemer’s vast experience will be tremendously helpful to Pathway as we continue our rapid growth both here and abroad,” said Jim Plante, Pathway Genomics’ founder and CEO.  

Pathway Genomics Announces Partnership with PROMPT Patient Registry to Advance Hereditary Cancer Research

Posted on 11/17/2014 in News, Press Releases

promptlogo
SAN DIEGO, CANovember 17, 2014Pathway Genomics Corporation, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced today that it has partnered with the Prospective Registry of Multiplex Testing (PROMPT), an online registry for patients who have undergone testing for cancer-causing genetic mutations. PROMPT is a recently formed consortium of physicians and scientists at academic centers across the nation, including Memorial Sloan Kettering Cancer Center, Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania, and the Dana-Farber Cancer Institute. "We are honored to collaborate with the country’s leading cancer experts to help advance the understanding of cancer risk, the genes associated with it, and take steps to end preventable hereditary cancers,” said David Becker, Ph.D., Pathway Genomics’ chief scientific officer. The goal of the registry is to provide vital data needed to better understand the level of risk associated with and outcomes following testing for “panels” of cancer-associated genes. Key milestones were reached this summer, with the completion of the patient online portal in July and ethical approval in August to begin to patient enrollment on the first phase of the study.  

Former Chair of Medicine at Cedars-Sinai Medical Center Glenn D. Braunstein, M.D., Joins Pathway Genomics’ Medical Advisory Board

Posted on 11/06/2014 in News, Press Releases

Pathway Genomics announced that world-renowned endocrinologist Dr. Glenn D. Braunstein has joined Pathway Genomics’ medical advisory board. Dr. Braunstein is currently the vice president of clinical innovation, director of the Thyroid Cancer Center and professor of medicine at Cedars-Sinai. For 26 years he served as chair of the Department of Medicine at Cedars-Sinai, and holds the James R. Klinenberg, M.D., Chair in Medicine. “We are honored to have Dr. Braunstein on our medical advisory board, and we look forward to his expert contributions as we rapidly grow our commercial and research divisions,” said Jim Plante, Pathway Genomics’ founder and CEO. “His vast knowledge and veteran experience in medicine will help us continue to enhance and deliver clinically useful genetic tests to physicians and patients.”  

Twitter Stream


Recent Posts

Search Posts